Rallybio Announces First-in-Human Dosing in RLYB211 Phase 1/2 Study. RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns. NEW HAVEN, Conn., November 10, 2020. Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and ...
FREE to attend, RAREfest20 is a full day festival featuring interactive exhibits showcasing cool science, visionary technology and pioneering organisations, improving lives and bringing hope to those affected by rare diseases. In true 2020 style, RAREfest20 promises to be a virtual feast that will spark curiosity, challenge perceptions, showcase science, inspire innovation and give ...- Severe thrombocytopenia leading to bleeding into major organs, including intracranial haemorrhage (ICH) can result in miscarriage, loss of the newborn or severe life-long neurological disability. The following animation explaining Fetal and neonatal alloimmune thrombocytopenia has been made by Rallybio, who are in the process of developing a prophylactic treatment to prevent maternal antibodies destroying fetal ...
- 2019 American Journal of obstetrics. AJOG. Important study regarding M281, a monoclonal anti-FcRn antibody. If the study eventually shows blocking of FcRn with Nipocalimab is a safe and effective way to manage HDFN, the same strategy could be applied to FNAIT. This once a week treatment was well tolerated in a Phase 1 study in ...
1 June 2020. FNAIT progess update from: James B Bussel, MD. Pediatric Hematology & Oncology New York, NY Dear Members of NAITBABIES and the community interested in Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT): It gives me great pleasure to tell you about the progress that has been and is being made in regard to FNAIT. ...- Rallybio have announced the following news regarding financing, development and it’s Lead Product Candidate, RLY211. RLYB211 is a plasma-derived hyperimmune globulin in development for the prevention of FNAIT. Press release 19 May 2020 Rallybio Completes $145 Million Series B Financing and Announces Plans to Advance Lead Product Candidate into the Clinic in 2H 2020 ...
